The prognostic significance of DNA flow cytometry in breast cancer: results from 881 patients treated in a single centre

Camplejohn, R. S.; Ash, C. M.; Gillett, C. E.; Raikundalia, B.; Barnes, David J.; Gregory, WM; Richards, MA; Millis, R R

doi:10.1038/bjc.1995.29

Cited by 51 publications

(35 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Contradictory findings may result from differences in study design and technical, analytical and interpretative methods (15,(17)(18)(19)(20). Despite these limitations, the prognostic significance of DNA ploidy and SPF in breast cancer is relatively consensual, at least in univariate models (3,10,33). However, an important question remains in relation to the clinical utility and predictive value of DNA ploidy and SPF in the selection of adjuvant therapies.…”

Section: Discussionmentioning

confidence: 99%

“…Previous studies have indicated that the evaluation of cytometric parameters can improve the management of breast cancer, aiding in the prognostic assessment and therapeutic planning for patients (2)(3)(4)(5)(6)9,10,24). The current study aimed to review the application of DNA flow cytometry in the prognostic assessment of patients with breast cancer.…”

Section: Introductionmentioning

confidence: 99%

“…Numerous studies have reported that DNA ploidy and/or SPF are prognostic markers for breast cancer (2)(3)(4)(5)(6)(7)(8)(9)(10)(11); however, a number of studies have questioned their independent prognostic significance (12)(13)(14)(15). These conflicting data have limited the prognostic value of DNA flow cytometry and the extent of its clinical use.…”

Section: Introductionmentioning

confidence: 99%

“…In breast cancer, DNA ploidy and SPF have been investigated in association with the biological characterization of tumours, patient survival and prognosis (2)(3)(4)(5)(6)(7)(8)(9)(10)(11)(12)(13)(14)(15).…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Prognostic relevance of DNA flow cytometry in breast cancer revisited: The 25-year experience of the Portuguese Institute of Oncology of Lisbon

et al. 2017

View full text Add to dashboard Cite

Abstract. The potential prognostic significance of DNA flow cytometric measurements (DNA ploidy and S-phase fraction) in breast cancer remains in dispute. Inconclusive data, primarily due to the lack of consistent standardization and quality control programs, have limited its translation into clinical practice. The aim of the present review, based on the 25-year experience of the Portuguese Institute of Oncology of Lisbon, is to assess the clinical relevance and application of DNA flow cytometry for the prognosis of breast cancer. Overall, data from Portuguese Institute of Oncology of Lisbon indicate that DNA flow cytometry provides significant prognostic information that is biologically relevant and clinically useful for the management of patients with breast cancer. Furthermore, this data has demonstrated the independent value of DNA aneuploidy as a prognostic indicator of poor clinical outcome in various subgroups of patients with early or locally advanced breast cancer at short-and long-term follow-up. Notably, aneuploidy identifies subsets of patients with grade (G)1 or G2 tumours who exhibit a poor clinical outcome. These patients may benefit from adjuvant chemotherapy, particularly those with luminal A and luminal B/human epidermal growth factor-2-negative endocrine-responsive breast cancer. In conclusion, data from Portuguese Institute of Oncology of Lisbon reinforces the clinical importance and utility of DNA flow cytometric analysis, particularly DNA ploidy, in the prognostic assessment and therapeutic planning for patients with breast cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Prognostic relevance of DNA flow cytometry in breast cancer revisited: The 25-year experience of the Portuguese Institute of Oncology of Lisbon

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Flow cytometric (FCM) S-phase fraction (SPF) is generally considered to be a prognostic factor in breast cancer (1)(2)(3)(4)(5)(6)(7)(8)(9)(10)(11)(12)(13)(14). In well-trained laboratories it has repeatedly been shown to be an independent prognostic factor, in both retrospective (6,8 -14) and prospective (7) investigations.…”

mentioning

confidence: 99%

Improved DNA flow cytometric, DNA ploidy, and S‐phase reproducibility between 15 laboratories in analysis of breast cancer using generalized guidelines

et al. 2003

View full text Add to dashboard Cite

Background: Lack of generalized guidelines for DNA flow cytometric analysis (FCM) may be the main reason for its limited use in the clinical management of breast cancer. Methods: After an initial interlaboratory reproducibility study (Round I), we concluded that it was the evaluation of the DNA histograms rather than the technical performance of the analysis that was the main reason for discordant results between laboratories. Guidelines for the interpretation of DNA histograms were therefore drawn up. We present here data from a new reproducibility study (Round II) using these guidelines. Results: For 10 laboratories also participating in Round I, use of the guidelines increased the concordance in DNA ploidy status from 89% to 100% for the 46 samples used in both rounds. The concordance rate for SPF also increased; mean r s -value increased from 0.81 to 0.88, and mean kappa value

show abstract

DNA Flow Cytometry Does Not Predict 5- or 10-Year Recurrence Rates for T1-2 Node-Negative Breast Cancer

et al. 2000

View full text Add to dashboard Cite

Background: A small proportion of T1 or T2 nodenegative breast cancer tumors will recur in patients by 5 years, and more by 10 years. Results of recent studies have suggested improvement in overall survival with administration of adjuvant chemotherapy to all patients. More sensitive and specific methods are needed to identify patients at highest risk for recurrence who might benefit most from adjuvant therapy, saving others from unnecessary treatment. Some investigators have suggested DNA flow cytometry as a method to discriminate patients at greatest risk for recurrence. Hypothesis: DNA flow cytometry has predictive value for breast cancer recurrence in node-negative patients. Methods: The cancer registry of a medium-sized university-affiliated hospital was used to identify patients with T1-2 N0 M0 breast cancer treated with a uniform surgical approach and no adjuvant therapy who had completed at least 5 years of follow-up or had recurrence. Flow cytometric analysis was performed on paraffin-embedded specimens. Results: Of 115 patients, 92 (80%) had disease-free survival without recurrence and 23 (20%) had recurrence. Comparison of diploid and nondiploid tumors for likelihood of recurrence revealed no association (P=.79). Furthermore, the DNA index and S-phase fraction were not significantly different between recurrent and nonrecurrent groups.

show abstract

The prognostic significance of DNA flow cytometry in breast cancer: results from 881 patients treated in a single centre

Cited by 51 publications

References 25 publications

Prognostic relevance of DNA flow cytometry in breast cancer revisited: The 25-year experience of the Portuguese Institute of Oncology of Lisbon

Prognostic relevance of DNA flow cytometry in breast cancer revisited: The 25-year experience of the Portuguese Institute of Oncology of Lisbon

Improved DNA flow cytometric, DNA ploidy, and S‐phase reproducibility between 15 laboratories in analysis of breast cancer using generalized guidelines

DNA Flow Cytometry Does Not Predict 5- or 10-Year Recurrence Rates for T1-2 Node-Negative Breast Cancer

Contact Info

Product

Resources

About